Drug Type Synthetic peptide |
Synonyms Locilex, Pexiganan, Pexiganan acetate (USAN) + [2] |
Target- |
Mechanism Cell membrane permeability enhancers |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC122H210N32O22.C2H4O2 |
InChIKeyZYMCXUWEZQKVIO-IJAHCEAPSA-N |
CAS Registry172820-23-4 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetic foot infection | Phase 3 | US | 01 Jun 2014 | |
Diabetic foot ulcer | Phase 3 | US | 01 Aug 1994 | |
Diabetic ulcer | Phase 3 | US | 01 Aug 1994 | |
Diabetic Foot | Phase 3 | - | - | |
Impetigo | Phase 3 | US | - | |
Complicated skin and soft tissue infection | Phase 1 | US | - | - |
Phase 3 | 200 | Standard wound care+Topical pexiganan cream 0.8% (Topical Pexiganan Cream 0.8%) | kerrwovxiv(pmjgnkrpyc) = aflfbhcfpm pdkmihlkjm (iyudrlszwh, rwqsfaatph - cobfkmrqty) View more | - | 14 Jun 2017 | ||
Topical placebo cream (Topical Placebo Control) | kerrwovxiv(pmjgnkrpyc) = gwnxoamfio pdkmihlkjm (iyudrlszwh, tivmmocrxm - xuttzfniaj) View more | ||||||
Phase 3 | 189 | Standard wound care+Topical pexiganan cream 0.8% (Topical Pexiganan Cream 0.8%) | escjeshudo(eamcelnife) = xlvuoezpfy mfpeasmozt (qrtxpepefu, cgzgwongpo - phunetftyp) View more | - | 14 Jun 2017 | ||
Topical placebo cream (Topical Placebo Control) | escjeshudo(eamcelnife) = zqnjgtstai mfpeasmozt (qrtxpepefu, svtzojzkfb - cmwzaizpai) View more |